PE20000557A1 - DERIVATIVES OF 8-PHENYLXANTHINE - Google Patents
DERIVATIVES OF 8-PHENYLXANTHINEInfo
- Publication number
- PE20000557A1 PE20000557A1 PE1999000459A PE00045999A PE20000557A1 PE 20000557 A1 PE20000557 A1 PE 20000557A1 PE 1999000459 A PE1999000459 A PE 1999000459A PE 00045999 A PE00045999 A PE 00045999A PE 20000557 A1 PE20000557 A1 PE 20000557A1
- Authority
- PE
- Peru
- Prior art keywords
- purin
- dioxo
- tetrahydro
- methyl
- refers
- Prior art date
Links
- ACCCXSZCOGNLFL-UHFFFAOYSA-N 8-phenyl-3,7-dihydropurine-2,6-dione Chemical class N1C=2C(=O)NC(=O)NC=2N=C1C1=CC=CC=C1 ACCCXSZCOGNLFL-UHFFFAOYSA-N 0.000 title abstract 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 abstract 2
- -1 HYDROXY, CARBAMOYL Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 abstract 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 229940029575 guanosine Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000004712 monophosphates Chemical class 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A DERIVADOS DE 8-FENILXANTINA DE FORMULA I, DONDE R1, R2, Y R3 SON H, ALQUENILO, ALQUINILO, CICLOALQUILO, ALQUILCARBAMOILO; R4 O R5 JUNTO CON N FORMAN UN ANILLO DE 3-7 MIEMBROS CON 1-4 HETEROATOMOS, OPCIONALMENTE SUSTITUIDO CON 1-2 HALOGENO, HIDROXI, CARBAMOILO, HIDROXICARBONILO, ALCOXICARBONILO, AMINO, ENTRE OTROS; R6 ES H, ALQUILO; Y EL GRUPO -SO2NR4R5 EN LA POSICION 4 o 5 DEL FENILO. SON COMPUESTOS PREFERIDOS 3-(3-BUTIL-1-METIL-2,6-DIOXO-2,3,6,7-TETRAHIDRO-1H-PURIN-8-IL)-4-PROPOXI-N-PIRIDIN-4-ILBENCENOSULFONAMIDA, 4-ETOXI-3-(1-METIL-2,6-DIOXO-3-PROPIL-2,3,6,7-TETRAHIDRO-1H-PURIN-8-IL)-N-(1H-[1,2,4]TRIAZOL-3-IL)BENCENOSULFONAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN INHIBIDOR POTENTE DE FOSFODIESTERASA ESPECIFICA DE GUANOSINA 3`,5'-MONOFOSFATO CICLICA Y EN PARTICULAR DE LA FOSFODIESTERASA 5 POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE ANGINA, HIPERTENSION, FALLAS DE CORAZON CONGESTIVAS, INFARTO, ASMA, BRONQUITIS, DISFUNCION ERECTIL MASCULINA, DISFUNCION SEXUAL FEMENINA, GLAUCOMA, SINDROME DE INTESTINO IRRITABLEREFERS TO 8-PHENYLXANTHINE DERIVATIVES OF FORMULA I, WHERE R1, R2, AND R3 ARE H, ALKENYL, ALKINYL, CYCLOALKYL, ALKYLCARBAMOYL; R4 OR R5 TOGETHER WITH N FORM A RING OF 3-7 MEMBERS WITH 1-4 HETEROATOMES, OPTIONALLY SUBSTITUTED WITH 1-2 HALOGEN, HYDROXY, CARBAMOYL, HYDROXICARBONYL, ALCOXYCARBONYL, AMINO, AMONG OTHERS; R6 IS H, ALKYL; AND THE GROUP -SO2NR4R5 IN POSITION 4 or 5 OF THE PHENYL. PREFERRED COMPOUNDS ARE 3- (3-BUTYL-1-METHYL-2,6-DIOXO-2,3,6,7-TETRAHYDRO-1H-PURIN-8-IL) -4-PROPOXI-N-PYRIDIN-4-ILBENZENOSULFONAMIDE , 4-ETOXY-3- (1-METHYL-2,6-DIOXO-3-PROPYL-2,3,6,7-TETRAHYDRO-1H-PURIN-8-IL) -N- (1H- [1,2 , 4] TRIAZOL-3-IL) BENZENOSULFONAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. COMPOUND I IS A POTENT INHIBITOR OF SPECIFIC PHOSPHODIESTERASE OF GUANOSINE 3`, 5'-CYCLIC MONOPHOSPHATE AND IN PARTICULAR OF PHOSPHODIESTERASE 5 SO IT MAY BE USEFUL FOR THE TREATMENT OF ANGINA, HYPERTENSION, INFLUENZA DE CORASTIVAS BRONCHITIS, MALE ERECTILE DYSFUNCTION, FEMALE SEXUAL DYSFUNCTION, GLAUCOMA, IRRITABLE BOWEL SYNDROME
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES9801152 | 1998-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000557A1 true PE20000557A1 (en) | 2000-07-20 |
Family
ID=8304000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000459A PE20000557A1 (en) | 1998-06-03 | 1999-05-31 | DERIVATIVES OF 8-PHENYLXANTHINE |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR018619A1 (en) |
| AU (1) | AU4501199A (en) |
| CO (1) | CO5021199A1 (en) |
| PE (1) | PE20000557A1 (en) |
| WO (1) | WO1999062905A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2166270B1 (en) | 1999-07-27 | 2003-04-01 | Almirall Prodesfarma Sa | DERIVATIVES OF 8-PHENYL-6,9-DIHIDRO- (1,2,4,) TRIAZOLO (3,4-I) PURIN-5-ONA. |
| GB0007934D0 (en) * | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
| GB0008694D0 (en) * | 2000-04-07 | 2000-05-31 | Novartis Ag | Organic compounds |
| US7019136B2 (en) | 2000-04-07 | 2006-03-28 | Novartis, Ag | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors |
| US6919337B2 (en) | 2000-04-07 | 2005-07-19 | Novartis, Ag | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors |
| AU2001281802A1 (en) | 2000-06-07 | 2001-12-17 | Almirall Prodesfarma, S.A. | 6-phenylpyrrolopyrimidinedione derivatives |
| ATE374776T1 (en) * | 2000-08-09 | 2007-10-15 | Almirall Lab | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES |
| US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| CN1127506C (en) * | 2001-06-29 | 2003-11-12 | 刘宝顺 | Compound for treating impotence |
| CA2457944C (en) | 2001-08-28 | 2009-09-29 | Schering Corporation | Polycyclic guanine phosphodiesterase v inhibitors |
| WO2003042216A1 (en) | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
| EP3749697A4 (en) | 2018-02-05 | 2021-11-03 | Bio-Rad Laboratories, Inc. | CHROMATOGRAPHIC RESIN WITH A LIGAND WITH ANION EXCHANGE-HYDROPHOBIC MIXED MODE |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3347290A1 (en) * | 1983-12-28 | 1985-07-11 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW 2-PHENYL IMIDAZOLES, THEIR PRODUCTION AND MEDICINES CONTAINING THESE COMPOUNDS |
| GB8817651D0 (en) * | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
| GB9213623D0 (en) * | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
-
1999
- 1999-05-26 WO PCT/EP1999/003644 patent/WO1999062905A1/en not_active Ceased
- 1999-05-26 AU AU45011/99A patent/AU4501199A/en not_active Abandoned
- 1999-05-31 PE PE1999000459A patent/PE20000557A1/en not_active Application Discontinuation
- 1999-06-02 CO CO99034567A patent/CO5021199A1/en unknown
- 1999-06-02 AR ARP990102608A patent/AR018619A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU4501199A (en) | 1999-12-20 |
| WO1999062905A1 (en) | 1999-12-09 |
| CO5021199A1 (en) | 2001-03-27 |
| AR018619A1 (en) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000557A1 (en) | DERIVATIVES OF 8-PHENYLXANTHINE | |
| EA200200337A1 (en) | DERIVATIVES OF PYRAZOLO [4,3-d] PYRIMIDINE | |
| PE20030845A1 (en) | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | |
| PE20010854A1 (en) | USE OF SUBSTITUTED PYRIMIDINE 4 DERIVATIVES AS ANTAGONISTS OF GLUTAMATE mGluR1 RECEPTORS | |
| UY25671A1 (en) | PROCEDURE FOR PREPARING 2-PHENYL SUBSTITUTED IMIDAZOTRAZINONES | |
| CY1109329T1 (en) | Xanthines, inhibitors of type V phosphodiesterase | |
| PE20020228A1 (en) | ORGANIC COMPOUNDS AS INHIBITORS OF 3 ', 5' GUANOSIN CYCLIC MONOPHOSPHATE PHOSPHODIESTERASE | |
| PE20030759A1 (en) | USE OF BENZOTHIAZOLES UREAS | |
| EA200101203A1 (en) | DERIVATIVES OF PURIN | |
| PE20010401A1 (en) | DERIVATIVES OF 8-PHENYL-6,9-DIHYDRO- [1,2,4] TRIAZOL [3,4-i] PURIN-5-ONA AS INHIBITORS OF CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE | |
| PE20010736A1 (en) | PIRAZOLE- [4,3-d] -PYRIMIDIN-7-ONA AS INHIBITORS OF 3`, 5'-GUANOSINMONOPHOSPHATE CYCLIC PHOSPHODIESTERASE | |
| PE20020514A1 (en) | HETEROCYCLIC AMINES AND SUBSTITUTE PHENYLAZACICLOALKANES FOR THE TREATMENT OF RESTLESS LEGS SYNDROME | |
| PE20021155A1 (en) | QUINOLINE DERIVATIVES AS ANTAGONISTS OF NEUROPEPTIDES AND | |
| PE20020823A1 (en) | DERIVATIVES OF NUCLEOSIDES AS INHIBITORS OF RNA-DEPENDENT VIRAL RNA POLYMERASE | |
| PE20010629A1 (en) | TRIAZOLPYRIDINAMINE DERIVATIVES AS ADENOSINE RECEPTOR LINKS | |
| PE20011269A1 (en) | DERIVATIVES OF 9- (5-HETEROARYLTETRAHYDROFURANIL) -PURINE AS SELECTIVE AGONISTS OF THE ADENOSINE A2a RECEPTOR | |
| ES2192081T3 (en) | ANTI-VIRAL PURINE DERIVATIVES. | |
| PE20030415A1 (en) | POLYCYCLICAL DERIVATIVES OF GUANINE AS INHIBITORS OF PHOSPHODIESTERASE V | |
| DE3687601D1 (en) | (4-PIPERIDINYLMETHYL AND HETERO) PURINE. | |
| ATE161267T1 (en) | ANTIVIRAL 4'-THIO-PYRIMIDINE NUCLEOSIDE | |
| PE1998A1 (en) | BENZO DERIVATIVES [g] QUINOLINE | |
| UA27901C2 (en) | DERIVATIVES OF 7- (2-AMINOETHYL) BENZOTIAZOLONE EXPOSING AGONISTIC ACTIVITY IN RELATION TO BETA2-ADRENORECEPTORS, PHARMACATSYAPHYAT | |
| PE20020219A1 (en) | 6-PHENYLPYRROLPYRIMIDINDIONE DERIVATIVES AS PHOSPHODIESTERASE 5 INHIBITORS | |
| MY123083A (en) | Acyclic nucleoside derivatives | |
| ES8606304A1 (en) | A PROCEDURE FOR PREPARING TIAZINE DERIVATIVES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |